Ionis Pharmaceuticals (IONS) Other financing activities (2009 - 2026)

Ionis Pharmaceuticals' Other financing activities history runs 18 years deep, the most recent figure standing at $57.3 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 2456.98% year-over-year to $57.3 million in Q1 2026; TTM through Mar 2026 was $247.7 million, a 1923.24% increase from a year earlier, with the FY2025 full-year figure at $192.6 million, up 473.07% from the prior year.
• Other financing activities retreated to $57.3 million in Q1 2026 per IONS's latest filing, from $107.8 million in the prior quarter.
• Across five years, Other financing activities topped out at $500.0 million in Q1 2023 and bottomed at -$495.0 million in Q2 2023.
• The 5-year median for Other financing activities is $5.1 million (2022), against an average of $49.4 million.
• Biggest YoY gain for Other financing activities was 26956.28% in 2023; the steepest drop was 26688.42% in 2023.
• Year by year, Other financing activities stood at $6.4 million in 2022, then surged by 7609.4% to $491.3 million in 2023, then slumped by 99.92% to $402000.0 in 2024, then jumped by 26720.15% to $107.8 million in 2025, then plunged by 46.85% to $57.3 million in 2026.
• Per Business Quant, the three latest IONS Other financing activities figures stand at $57.3 million (Q1 2026), $107.8 million (Q4 2025), and $81.3 million (Q3 2025).